64 related articles for article (PubMed ID: 29550484)
1. Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells.
Girerd S; Tosca L; Herault O; Vignon C; Biard D; Aggoune D; Dkhissi F; Bonnet ML; Sorel N; Desterke C; Bennaceur-Griscelli A; Tachdjian G; Guilhot F; Guilhot J; Chomel JC; Turhan AG
Biochem Biophys Res Commun; 2018 Apr; 498(4):715-722. PubMed ID: 29550484
[TBL] [Abstract][Full Text] [Related]
2. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
[TBL] [Abstract][Full Text] [Related]
3. Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy.
Sandt C; Feraud O; Bonnet ML; Desterke C; Khedhir R; Flamant S; Bailey CG; Rasko JEJ; Dumas P; Bennaceur-Griscelli A; Turhan AG
Biochem Biophys Res Commun; 2018 Sep; 503(3):1861-1867. PubMed ID: 30057314
[TBL] [Abstract][Full Text] [Related]
4. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
5. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
6. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
[TBL] [Abstract][Full Text] [Related]
7. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG
Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417
[TBL] [Abstract][Full Text] [Related]
8. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
[TBL] [Abstract][Full Text] [Related]
9. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
10. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
[TBL] [Abstract][Full Text] [Related]
11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
12. Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Wang LX; Wang JD; Chen JJ; Long B; Liu LL; Tu XX; Luo Y; Hu Y; Lin DJ; Lu G; Long ZJ; Liu Q
Sci Rep; 2016 Nov; 6():35533. PubMed ID: 27824120
[TBL] [Abstract][Full Text] [Related]
13. The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.
Dkhissi F; Aggoune D; Pontis J; Sorel N; Piccirilli N; LeCorf A; Guilhot F; Chomel JC; Ait-Si-Ali S; Turhan AG
Exp Hematol; 2015 Sep; 43(9):775-80. PubMed ID: 26118501
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
15. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
[TBL] [Abstract][Full Text] [Related]
16. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
Chen M; Turhan AG; Ding H; Lin Q; Meng K; Jiang X
Oncotarget; 2017 Jul; 8(27):43662-43677. PubMed ID: 28599273
[TBL] [Abstract][Full Text] [Related]
17. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML).
Chomel JC; Sorel N; Bonnet ML; Bertrand A; Brizard F; Saulnier PJ; Roy L; Guilhot F; Turhan AG
Leuk Res; 2009 Apr; 33(4):551-5. PubMed ID: 18829107
[TBL] [Abstract][Full Text] [Related]
18. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
Watanabe T; Hotta C; Koizumi S; Miyashita K; Nakabayashi J; Kurotaki D; Sato GR; Yamamoto M; Nakazawa M; Fujita H; Sakai R; Fujisawa S; Nishiyama A; Ikezawa Z; Aihara M; Ishigatsubo Y; Tamura T
Cancer Res; 2013 Nov; 73(22):6642-53. PubMed ID: 24242069
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
20. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
